title: [Cyamemazine (Tercian®): Exploration of extrapyramidal syndrome cases contained in the French pharmacovigilance database].
abstract: OBJECTIVE
  Cyamemazine (Tercian®) is currently the most widely prescribed neuroleptic in France. This widespread use is due to its anxiolytics properties and to a claimed good safety profile. Although, prescription of cyamemazine is not devoid of the risks associated with the use of neuroleptics: extrapyramidal syndromes. This study aims at describing extrapyramidal syndromes induced by cyamemazine registered in the French pharmacovigilance database.
  
  
  METHODS
  All spontaneous reports of extrapyramidal syndromes in the French pharmacovigilance database between 1st January 1985 and 31th December 2015 were described and analyzed.
  
  
  RESULTS
  During this period 132 cases following cyamemazine intake were reported in the French pharmacovigilance database. The extrapyramidal syndromes were considered as "serious" in 77% of cases. More than 80% of the cases were described with a dosage of cyamemazine under 100mg/day and no correlation between drug dose and seriousness of the cases were found. Thirty-six cases were described with a monotherapy of cyamemazine.
  
  
  CONCLUSIONS
  We should keep in mind that despite its widespread use in various indications (e.g. anxiolytic) cyamemazine remains a neuroleptic and could induce extrapyramidal syndromes even with low dosage. Careful monitoring should be performed when introducing and with long-term use of cyamemazine, mostly in elderly patients or patient already being treated with neuroleptics.
authors.affiliation: Centre régional de pharmacovigilance, CHU de Grenoble, pavillon E, CS 10217, 38043 Grenoble cedex 09, France. Electronic address: ckhouri@chu-grenoble.fr.
authors.forename: Charles
authors.initials: C
authors.lastname: Khouri
authors.affiliation: Centre régional de pharmacovigilance, CHU de Grenoble, pavillon E, CS 10217, 38043 Grenoble cedex 09, France.
authors.forename: Marion
authors.initials: M
authors.lastname: Lepelley
authors.affiliation: Centre régional de pharmacovigilance, CHU de Grenoble, pavillon E, CS 10217, 38043 Grenoble cedex 09, France.
authors.forename: Céline
authors.initials: C
authors.lastname: Villier
authors.affiliation: Clinique de psychiatrie, pôle neurologie psychiatrie, CHU de Grenoble, 38043 Grenoble, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Bougerol
authors.affiliation: Centre régional de pharmacovigilance, CHU de Grenoble, pavillon E, CS 10217, 38043 Grenoble cedex 09, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Mallaret
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000453:epidemiology; D062313:Databases, Pharmaceutical; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D060735:Pharmacovigilance; D010640:Phenothiazines / Q000009:adverse effects*
chemical_list: D014150:Antipsychotic Agents; D010640:Phenothiazines; C028457:cyamemazine
keywords: Cyamemazine; Cyamémazine; Extrapyramidal syndromes; Pharmacovigilance; Syndromes extrapyramidaux